GW Pharmaceuticals PLC (NASDAQ:GWPH)

113.75
BATS BZX Real-Time Price
As of 12:46pm ET
 -2.32 / -2.00%
Today’s Change
58.16
Today|||52-Week Range
126.78
+68.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$2.5B

Company Description

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and Pipeline Research & Development. The Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.

Contact Information

GW Pharmaceuticals Plc
Sovereign House
Cambridge Cambridgeshire CB24 9BZ
P:441223266800
Investor Relations:
(917) 280-2424

Employees

Shareholders

Mutual fund holders38.81%
Other institutional15.93%
Individual stakeholders--

Top Executives

Justin D. GoverChief Executive Officer & Executive Director
Christopher John ToveyChief Operating Officer & Executive Director
Adam David GeorgeCFO, Secretary & Executive Director
Richard PottsDirector-Clinical Operations
Colin StottDirector-Research & Development Operations

To view my watchlist

Not a member yet?

Sign up now for a free account